title: Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder.
abstract: BACKGROUND
  The 33-item Overactive Bladder questionnaire (OAB-q; 1-week recall version) has been psychometrically validated in middle-aged, generally healthy patients with overactive bladder. The present analysis was conducted to determine the psychometric validity of the OAB-q in medically complex elderly patients.
  
  
  METHODS
  OAB-q structure was evaluated using a second-order confirmatory factor analysis (CFA) model with five domains and one aggregated domain, using pooled data from two clinical trials (786 observations) for urgency urinary incontinence (UUI). Psychometric validity was evaluated with CFA, Cronbach coefficient α (CCA) for reliability, Spearman correlations for convergent validity, differences in OAB-q scores in relation to UUI severity and Patient Perception of Bladder Condition (PPBC) scores for known-groups validity, and effect size (ES) of differences in mean scores of OAB-q domains over time for treatment responsiveness.
  
  
  RESULTS
  Participants were predominantly female (82.2%) and white (85.9%); mean age was 75.0 years. The second-order CFA was confirmed with a Bentler's comparative fit index of 0.90, t values for path coefficients of >1.96, and standardized path coefficients of >0.40. OAB-q domains demonstrated good internal consistency (CCA >0.7). Convergent validity was supported by moderate correlations (0.4-0.7) between OAB-q domain and PPBC scores. Significant differences in OAB-q domain scores between groups with different symptom severity established known-groups validity. Significant changes in mean OAB-q scores from baseline to week 12 with moderate-to-large ES (0.50-0.80) demonstrated treatment responsiveness.
  
  
  CONCLUSIONS
  The OAB-q demonstrates reliability, concurrent and discriminant validity, and responsiveness to treatment. The evidence shows that the OAB-q is psychometrically sound for use in medically complex elderly patients with overactive bladder.
authors.affiliation: Outcomes & Evidence, Global Health & Value Pfizer Inc, 235 East 42nd Street, New York, NY, 10017, USA. Alexandra.Barsdorf@pfizer.com.
authors.forename: Alexandra I
authors.initials: AI
authors.lastname: Barsdorf
authors.affiliation: Outcomes & Evidence, Global Health & Value Pfizer Inc, 235 East 42nd Street, New York, NY, 10017, USA.
authors.forename: Martin
authors.initials: M
authors.lastname: Carlsson
authors.affiliation: Pfizer Inc, Groton, CT, USA.
authors.forename: Andrew G
authors.initials: AG
authors.lastname: Bushmakin
authors.affiliation: Outcomes & Evidence, Global Health & Value Pfizer Inc, 235 East 42nd Street, New York, NY, 10017, USA.
authors.forename: Sheila
authors.initials: S
authors.lastname: Quinn
authors.affiliation: Pfizer Inc, Groton, CT, USA.
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Cappelleri
authors.affiliation: Pfizer Inc, La Jolla, CA, USA.
authors.forename: Andreas
authors.initials: A
authors.lastname: Pleil
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D005163:Factor Analysis, Statistical; D005260:Female; D006801:Humans; D008297:Male; D000071066:Patient Reported Outcome Measures; D011594:Psychometrics; D011788:Quality of Life; D015203:Reproducibility of Results; D018709:Statistics, Nonparametric; D011795:Surveys and Questionnaires / Q000592:standards*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy / Q000523:psychology*; D064804:Urological Agents / Q000008:administration & dosage*
chemical_list: D001559:Benzhydryl Compounds; D064804:Urological Agents; C526675:fesoterodine
keywords: Medically complex elderly; Overactive bladder; Overactive bladder questionnaire; Patient-reported outcomes; Psychometric validation